How PSI CRO Transformed Clinical Trial Processes with AI and Contextual Data

Introduction

In the competitive world of clinical research, the speed and efficiency of trial site selection can substantially influence the success of a drug development program. PSI CRO, a leading global clinical research organization, has revolutionized this process by dramatically cutting the time required to identify suitable clinical trial sites from weeks to a matter of minutes. This remarkable transformation is powered by their implementation of the SYNETIC™ platform, built on Arango's advanced contextual data capabilities.

The Challenges of Clinical Trials

Selecting the right sites for clinical trials is a pivotal and costly decision. Traditionally, the process has been hampered by inefficiencies, with as many as 30-40% of trial sites under-enrolling and 15% failing to recruit any patients at all. With operational costs escalating, the pressure is on to optimize resources and increase the efficiency of clinical trials. It can cost upwards of $30,000 to activate a single trial site, and when numerous sites underperform, it can lead to losses amounting to millions of dollars over the course of a study.

Unifying Disparate Data

Despite the plethora of data that clinical research organizations gather, including historical trial information and investigator profiles, this critical knowledge is frequently fragmented across various systems. This disaggregation hampers the ability to make informed decisions about which sites will perform best. PSI recognized that to effectively tackle these challenges, they needed to centralize and simplify their data collection.

The SYNETIC™ Solution

To overcome these obstacles, PSI CRO established SYNETIC™, a state-of-the-art AI-driven knowledge engine that leverages the Arango Contextual Data Platform. This platform consolidates structured data, documentation, and historical information into a unified contextual layer that represents relationships among investigators, institutions, study protocols, and outcomes. By employing a multimodel approach that integrates graph relationships, vector embeddings, and search capabilities, PSI can now analyze extensive clinical research data, recognizing critical patterns across vast repositories of historical data.

Speeding Up Site Selection

With SYNETIC™, PSI teams can now generate informed site recommendations in a fraction of the time. The previously arduous task of compiling a list of potential trial sites, which could take weeks, can now be completed in mere minutes. This efficiency not only speeds up trial timelines but also reduces the inclusion of non-enrolling sites, ultimately saving substantial costs during the clinical trial process.

Explainable AI for Transparency

In the highly regulated realm of clinical trials, transparency and accountability are essential. SYNETIC™ addresses this need by providing explainable AI solutions. It offers detailed insights into site selection processes, including the rationale behind certain recommendations, supporting evidence from historical data, confidence levels for predictions, and any potential knowledge gaps that may exist. This layer of transparency fosters trust in AI-driven decisions, allowing researchers to leverage AI intelligently while adhering to the stringent standards of the healthcare industry.

Industry-Wide Implications

PSI's success with SYNETIC™ highlights a broader trend emerging across various industries, emphasizing the importance of contextual data infrastructure in deploying successful AI initiatives. The Arango Contextual Data Platform serves as the backbone for future-ready organizations, facilitating seamless access to integrated data across siloed systems and optimizing the connections between personnel, processes, and outcomes.

Conclusion

As the healthcare landscape continues to evolve, the integration of AI technologies and contextual data will be increasingly vital for clinical research organizations. PSI CRO's advancements through SYNETIC™ exemplify how a unified contextual data layer can transform clinical trial site selection, enhance efficiency, and ultimately lead to better patient outcomes. Looking ahead, this innovation will likely set a new benchmark for clinical trial processes, encouraging other organizations to explore similar integrations to stay competitive in the evolving field of drug development.